Literature DB >> 19708117

Determination of the structure of human phosphodiesterase-2 in a bound state and its binding with inhibitors by molecular modeling, docking, and dynamics simulation.

Adel Hamza1, Chang-Guo Zhan.   

Abstract

Although an X-ray crystal structure of the catalytic domain of human cyclic nucleotide phosphodiesterase-2 (PDE2A) was reported in the literature, the shape of the binding pocket is not suitable for binding with its known potent inhibitors. Extensive molecular modeling, docking, and dynamics simulations in the present study have demonstrated for the first time that the structure of PDE2A catalytic domain may exist in two different forms corresponding to the inhibitor-bound and unbound states of the enzyme. The structural change from the unbound state to the bound state leads to a substantial variation in the size of the pocket but does not affect the general structural feature of the catalytic site. The flexible binding pocket and conserved structural feature of the catalytic site lead us to better understand why this enzyme can catalyze hydrolysis of two different intercellular second messengers. It has been demonstrated that the available X-ray crystal structure of PDE2A was in the unbound state, explaining why it is not suitable for molecular docking studies on the enzyme-inhibitor binding. We have developed a reasonable 3D model of the PDE2A structure in the bound state and determined the detailed binding modes and binding free energies for PDE2A binding with its known potent inhibitors. The calculated binding free energies are in good agreement with available experimental data. The general structural insights, PDE2A model in the bound state, and detailed PDE2A-inhibitor binding structures obtained in this study will be valuable for future rational design of novel, potent inhibitors of PDE2A as therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19708117     DOI: 10.1021/jp8082612

Source DB:  PubMed          Journal:  J Phys Chem B        ISSN: 1520-5207            Impact factor:   2.991


  7 in total

1.  Computational determination of binding structures and free energies of phosphodiesterase-2 with benzo[1,4]diazepin-2-one derivatives.

Authors:  Bo Yang; Adel Hamza; Guangju Chen; Yan Wang; Chang-Guo Zhan
Journal:  J Phys Chem B       Date:  2010-11-15       Impact factor: 2.991

2.  Novel human mPGES-1 inhibitors identified through structure-based virtual screening.

Authors:  Adel Hamza; Xinyun Zhao; Min Tong; Hsin-Hsiung Tai; Chang-Guo Zhan
Journal:  Bioorg Med Chem       Date:  2011-08-25       Impact factor: 3.641

3.  Microscopic Modes and Free Energies for Topoisomerase I-DNA Covalent Complex Binding with Non-campothecin Inhibitors by Molecular Docking and Dynamics Simulations.

Authors:  Ning-Ning Wei; Adel Hamza; Ce Hao; Zhilong Xiu; Chang-Guo Zhan
Journal:  Theor Chem Acc       Date:  2013-08       Impact factor: 1.702

4.  Fundamental reaction mechanism and free energy profile for (-)-cocaine hydrolysis catalyzed by cocaine esterase.

Authors:  Junjun Liu; Adel Hamza; Chang-Guo Zhan
Journal:  J Am Chem Soc       Date:  2009-08-26       Impact factor: 15.419

5.  The single cyclic nucleotide-specific phosphodiesterase of the intestinal parasite Giardia lamblia represents a potential drug target.

Authors:  Stefan Kunz; Vreni Balmer; Geert Jan Sterk; Michael P Pollastri; Rob Leurs; Norbert Müller; Andrew Hemphill; Cornelia Spycher
Journal:  PLoS Negl Trop Dis       Date:  2017-09-15

6.  Long-Timescale Simulations Revealed Critical Non-Conserved Residues of Phosphodiesterases Affecting Selectivity of BAY60-7550.

Authors:  Qing Liu; Menghua Song; Yue Qiu; Elaine Lai-Han Leung; Qiang Huang; Xiaojun Yao
Journal:  Comput Struct Biotechnol J       Date:  2022-09-13       Impact factor: 6.155

7.  Arylquins target vimentin to trigger Par-4 secretion for tumor cell apoptosis.

Authors:  Ravshan Burikhanov; Vitaliy M Sviripa; Nikhil Hebbar; Wen Zhang; W John Layton; Adel Hamza; Chang-Guo Zhan; David S Watt; Chunming Liu; Vivek M Rangnekar
Journal:  Nat Chem Biol       Date:  2014-09-14       Impact factor: 15.040

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.